Estimates Vary Widely for Number of Wuhan COVID-19 Cases in January

Lacking many diagnostic test results from the first major outbreak, researchers have been left to scour other sources for clues about what happened in the early days of the pandemic.

Written byChris Baraniuk
| 5 min read
wuhan china coronavirus pandemic covid-19 estimate modeling cases

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ABOVE: Wuhan, China, January 24, 2020
© ISTOCK.COM, JULIEN VIRY

Five months since COVID-19 exploded in Wuhan, researchers still don’t know exactly how many people caught the disease in the city during those crucial early days of the outbreak. At the heart of this problem is the fact that testing in the city of 11 million people was very limited in those early days of the outbreak. By January 23, the first day of the city’s lockdown, just 495 cases had been officially confirmed.

As one researcher based in Hong Kong puts it, Chinese authorities were clearly aware that they had a much bigger problem on their hands than that number suggested.

“They decided to build the hospitals, they sent doctors to Wuhan,” says Daihai He, a mathematical epidemiologist at Hong Kong Polytechnic University, referring to two hospitals with capacity for more than 2,500 people that were constructed in early February ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • chris baraniuk

    Chris Baraniuk is a freelance science journalist based in Northern Ireland who contributes to The Scientist. He has covered biological and medical science for a range of publications, including the BBC, the BMJ, and Mosaic. He also writes about nature, climate change, and technology. His background in the humanities has long proved invaluable in his quest to bring science stories to people from all walks of life.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies